Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib (ATC-Code nach WHO: L01EA03)
Opportunity Score
Why this score?
Opportunity
70 / 100
Complexity
40 / 100
Risk factors
No minimum volume; actual demand depends on prescription behavior and patient numbers.
Buyer may terminate if exclusive agreements (typically after 8-12 months) are concluded.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jul 2026
- Supply of Nilotinib (ATC L01EA03) under a non-exclusive framework agreement.
- Excludes Nilotinib dispersed in apple sauce unless patented.
Show full summary
Non-exclusive drug discount agreement for Nilotinib (ATC L01EA03) via an Open-House model. Contract ends 31.07.2026. Open to all qualified pharmaceutical entrepreneurs meeting German statutory requirements. No guaranteed volumes or exclusivity. Estimated value not published. Submission possible periodically until final deadline.
Risks
No minimum volume; actual demand depends on prescription behavior and patient numbers.
Buyer may terminate if exclusive agreements (typically after 8-12 months) are concluded.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG for the offered medicinal products.
- Legal seat within Germany, EU, or EEA (§9 Abs. 2 AMG).
Eligibility
- No exclusion grounds under §§123, 124 GWB (submission of self-declaration).
Requirements may be incomplete.
Buyer
Name
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib
Single lot covering Nilotinib (excluding apple sauce dispersion unless patented). Open House model – any qualified pharmaceutical entrepreneur may join by submitting required documents. No negotiation or exclusivity.
Location
Duration
Category
Deadline
Award details
Selection criteria
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Nilotinib (ATC-Code nach WHO: L01EA03)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 29 May 2025
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 349678-2025
Documents (1)
Similar tenders
Sweden – Repair and maintenance services – Hisservice Södra Sverige, ramavtal
Germany – Construction work for school buildings – 302-01 Baumeisterarbeiten | Erweiterung und Generalsanierung Realschule Thannhausen
Poland – Engineering services – Wykonanie kompleksowej, wielobranżowej dokumentacji projektowej dla inwestycji pn.: Rozbudowa Estakady Kwiatkowskiego w Gdyni
France – Architectural services for outdoor areas – Mission de maîtrise d'oeuvre pour la construction d'une télécabine entre Bozel - Saint-Bon - Courchevel Village
Switzerland – Building construction work – BAV 59016 Recyclingzentrum Juch-Areal, Neubau Juch-Areal - BKP 214 Montagebau in Holz
Switzerland – Architectural, engineering and planning services – Zukunftfähiges OT-RZ
Opportunity Score
Why this score?
Opportunity
70 / 100
Complexity
40 / 100
Risk factors
No minimum volume; actual demand depends on prescription behavior and patient numbers.
Buyer may terminate if exclusive agreements (typically after 8-12 months) are concluded.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications